<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AZELASTINE HYDROCHLORIDE</span><br/>(a-ze-las'teen)<br/><span class="topboxtradename">Astelin, </span><span class="topboxtradename">Optivar<br/></span><b>Classifications:</b> <span class="classification">antihistamine</span>; <span class="classification">h<sub>1</sub>-receptor antagonist</span>; <span class="classification">ocular antihistamine</span><br/><b>Prototype: </b>Diphenhydramine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>137 mcg/spray nasal spray; 0.05% ophthalmic solution</p>
<h1><a name="action">Actions</a></h1>
<p>First generation antihistamine that is a potent histamine H<sub>1</sub> receptor antagonist.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective in the symptomatic treatment of seasonal allergic rhinitis and as a nasal decongestant.</p>
<h1><a name="uses">Uses</a></h1>
<p>Seasonal allergic rhinitis, itching associated with allergic conjunctivitis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to azelastine; concurrent use of CNS depressants; pregnancy (category C), lactation, children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic or renal disease; children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Allergic Rhinitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Intranasal</span> 2 sprays per nostril b.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">Intranasal</span>
<i>511 y</i>, 1 spray per nostril b.i.d.<br/><br/><p><span class="rdpostnotetitle">Allergic Conjunctivitis</span><br/><span class="rdpostnotetext">
<b>See Appendix A-1.</b>
</span></p>
</td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intranasal</span><br/><ul>
<li>Prime delivery unit before first use (see manufacturer's instructions).</li>
<li>Instruct patient to clear nasal passages prior to drug installation; then tilt head forward slightly and sniff gently when
            drug is sprayed into each nostril.
         </li>
<li>Store the bottle upright at room temperature, 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Fatigue, dizziness. <span class="typehead">GI:</span> Dry mouth, nausea. <span class="typehead">Metabolic:</span> Weight gain. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache, somnolence</span>. <span class="typehead">Respiratory:</span> Pharyngitis, <span class="speceff-common">rhinitis,</span> paroxysmal sneezing, <span class="speceff-common">cough,</span> asthma. <span class="typehead">Special Senses:</span>
<span class="speceff-common">Bitter taste,</span> nasal burning, epistaxis, conjunctivitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> and <span class="classification">cns depressants</span> may cause reduced alertness. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 40% absorbed from nasal inhalation. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Metabolism:</span> Metabolized by CYP450 to active metabolites. <span class="typehead">Elimination:</span> Excreted primarily in feces. <span class="typehead">Half-Life:</span> 22 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor level of alertness especially in older adults and with concurrent use of other CNS depressants.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Follow manufacturer's directions for priming the metered dose spray unit before first use and after storage of &gt;3 d.</li>
<li>Tilt head forward while instilling spray. Avoid getting spray in eyes.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Avoid concurrent use of CNS depressants, such as alcohol, while taking this drug.</li>
<li>Discard spray unit and dispensing package bottle after 3 mo.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>